Podcast: Celltrion’s Subcutaneous Infliximab And The Future Of Biosimilars

We Discuss The Celltrion Product Breaking New Ground For Biosimilars

 
• By Dave Wallace

In this podcast discussion, Generics Bulletin’s David Wallace talks to Informa Pharma Consulting’s Duncan Emerton about Celltrion’s CHMP nod for subcutaneous Remsima, the product’s imminent approval and launch, and what it means for the future of biosimilars.

Microphone
David Wallace And Duncan Emerton Discuss Celltrion’s Subcutaneous Remsima • Source: Shutterstock

More from Biosimilars

More from Products